Objective Long-term azithromycin treatment effectively prevents acute exacerbations of chronic obstructive pulmonary disease ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

In February 2025 Harbour BioMed announced that the IND application for HBM9378 (SKB378), a TSLP-targeting monoclonal antibody ...

Antibiotic demand for pneumonia and COPD in the top 20 countries showed high global consumption. Researchers conducted a ...

It is becoming increasingly recognized that people with COPD have an elevated risk of serious CV events,1 discussed Hanania ...

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best hot stocks to buy according to Wall Street analysts. Earlier in May ...

Bronchiectasis is one of the most neglected chronic lung diseases despite the fact it impacts 300,000 people in the UK ...

In smokers with COPD, LABA+LAMA is more effective than LABA+ICS in preventing exacerbations, regardless of blood eosinophil count.

The study followed 351 patients across four Korean hospitals who had received anti-tuberculosis treatment for more than six months. These individuals were monitored over 11 years (132 months) to ...

Bronchiectasis causes your airways, called bronchi, to become damaged and widened over time. When you have bronchiectasis, ...

Dr Anna Moore and Catherine Furlong explain how singing can improve lung health for people with chronic respiratory disease ...

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...